Commercial trait embryo selection

Fertility startups are moving beyond disease screening to sell polygenic trait predictions for embryos — including IQ, height, ADHD risk, and appearance — by combining whole‑genome sequencing with consumer genomics pipelines. These products claim measurable shifts (single‑digit IQ point gains, reduced disease probabilities) despite major scientific uncertainty about prediction, transferability from adults to embryos, and environmental interactions. — If commercial trait selection scales, it will force policy, ethical, and inequality debates about reproductive choice, regulation, and the distributional effects of genetic advantage.